TGFB1 and melanoma: In humans, intrinsic resistance of melanoma to α-PD-1 therapy has been associated with a transcriptomic signature enriched for markers of EMT, immune suppression and macrophage chemotaxis [13], all of which can be driven by TGFβ signaling [11, 12, 14, 15].